borderline significantP = 0.056
Three additional trials were carried out in India ( 30 ), Ghana ( 31 ), and Tanzania ( 32 ) that demonstrated no impact on infant mortality, but in India there was a borderline significant reduction in mortality at 6 mo with NVAS (RR: 0.90, 95% CI: 0.81–1.00, P = 0.056).